Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 10/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845295 | 0.91 | LPAR1 (0.62) | LPAR1SCN9AGPR132NOX1CSNK2A2 | |
| SCHEMBL13464509 | 0.91 | LPAR1 (0.65) | LPAR1GPR132HDAC1 | |
| SCHEMBL1808339 | 0.89 | LPAR1 (0.58) | LPAR1SCN9AGPR132NOX1CSNK2A2 | |
| SCHEMBL1808335 | 0.89 | LPAR1 (0.58) | LPAR1SCN9AGPR132NOX1CSNK2A2 | |
| SCHEMBL1808336 | 0.89 | LPAR1 (0.58) | LPAR1SCN9AGPR132NOX1CSNK2A2 | |
| SCHEMBL1810479 | 0.87 | LPAR1 (0.51) | LPAR1SCN9AGPR132NOX1CSNK2A2 | |
| SCHEMBL1810483 | 0.87 | LPAR1 (0.51) | LPAR1SCN9AGPR132NOX1CSNK2A2 | |
| SCHEMBL1810481 | 0.87 | LPAR1 (0.51) | LPAR1SCN9AGPR132NOX1CSNK2A2 | |
| SCHEMBL13464633 | 0.85 | LPAR1 (0.69) | LPAR1NOX1HDAC1 | |
| SCHEMBL6845296 | 0.84 | LPAR1 (0.62) | LPAR1GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | LPAR1 4/4885SCN9A 3363/4885GPR132 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.